Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
Institut Gustave Roussy · Université Paris-Sud · +16 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
874
total citations
- FWCI
- 53.62
- Percentile
- 100%
- References
- 38
Citations per year
Authors
16Topics & keywords
Topics
Keywords
- Trametinib
- Dabrafenib
- Medicine
- MEK inhibitor
- Lung cancer
- Adverse effect
- Internal medicine
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.